1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => OpenAccess
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)


  
    



















































































































































































    Safety of Oral P2Y12 Inhibitors in Interventional Neuroradiology: Current Status and Perspectives | American Journal of Neuroradiology  
    



















    































    
  
  




    
    

  

      


    

      

  
  
  

    

  

    

  

                
    

      

  

    

  
      
  
  

    


Advertisement



  



  


  
  



  



    

  


  


  


  
  
  
  
  
  

  	      


    
      

    
  
    
        
    

  

    
                        

  

                
    

      

	  

		
		

			

			  

  
      
  
  

    

  
  
      
Review ArticleInterventional

  
      
Open Access

  
      
Safety of Oral P2Y12 Inhibitors in Interventional Neuroradiology: Current Status and Perspectives
  
    	
L.M. Camargo, P.C.T.M. Lima, K. Janot and I.L. Maldonado

  
    	
American Journal of Neuroradiology December 2021,  42 (12) 2119-2126; DOI: https://doi.org/10.3174/ajnr.A7303 

  
  
  



  


  
  



			

		

	
	
 	
	  
  

		
		

			

			  

  
      
  
  

    
  


  
  



  
      
  
  

    

  

    

  
      
  
  

    
References
  1. 1.↵
    1. Gorelick  PB, 
    2. Farooq  MU
    . Advances in our understanding of “resistance” to antiplatelet agents for prevention of ischemic stroke. Stroke Res Treat 2013;2013:727842 doi:10.1155/2013/727842 pmid:23936730
    CrossRefPubMed
  2. 2.↵
    1. Lee  DH, 
    2. Arat  A, 
    3. Morsi  H, et al
    . Dual antiplatelet therapy monitoring for neurointerventional procedures using a point-of-care platelet function test: a single-center experience. AJNR Am J Neuroradiol 2008;29:1389–94 doi:10.3174/ajnr.A1070 pmid:18483190
    CrossRefPubMed
  3. 3.↵
    1. Muller-Schunk  S, 
    2. Linn  J, 
    3. Peters  N, et al
    . Monitoring of clopidogrel-related platelet inhibition: correlation of nonresponse with clinical outcome in supra-aortic stenting. AJNR Am J Neuroradiol 2008;29:786–91 doi:10.3174/ajnr.A0917 pmid:18223094
    Abstract/FREE Full Text
  4. 4.↵
    1. Pandya  DJ, 
    2. Fitzsimmons  BF, 
    3. Wolfe  TJ, et al
    . Measurement of antiplatelet inhibition during neurointerventional procedures: the effect of antithrombotic duration and loading dose. J Neuroimaging 2010;20:64–69 doi:10.1111/j.1552-6569.2008.00322.x pmid:19018951
    CrossRefPubMedWeb of Science
  5. 5.↵
    1. Prabhakaran  S, 
    2. Wells  KR, 
    3. Lee  VH, et al
    . Prevalence and risk factors for aspirin and clopidogrel resistance in cerebrovascular stenting. AJNR Am J Neuroradiol 2008;29:281–85 doi:10.3174/ajnr.A0818 pmid:17989373
    CrossRefPubMed
  6. 6.↵
    1. Wagner  H, 
    2. Angiolillo  DJ, 
    3. ten Berg  JM, et al
    . Higher body weight patients on clopidogrel maintenance therapy have lower active metabolite concentrations, lower levels of platelet inhibition, and higher rates of poor responders than low body weight patients. J Thromb Thrombolysis 2014;38:127–33 doi:10.1007/s11239-013-0987-8 pmid:24043374
    CrossRefPubMed
  7. 7.↵
    1. Falcao  FJ, 
    2. Carvalho  L, 
    3. Chan  M, et al
    . P2Y12 platelet receptors: importance in percutaneous coronary intervention. Arq Bras Cardiol 2013;101:277–82 doi:10.5935/abc.20130162 pmid:23917456
    CrossRefPubMed
  8. 8.↵
    1. Wang  Y, 
    2. Wang  Y, 
    3. Zhao  X, et al
    . Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med 2013;369:11–19 doi:10.1056/NEJMoa1215340 pmid:23803136
    CrossRefPubMedWeb of Science
  9. 9.↵
    1. Johnston  SC, 
    2. Easton  JD, 
    3. Farrant  M, et al
    . Clinical Research Collaboration, Neurological Emergencies Treatment Trials Network, and the POINT Investigators. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA. N Engl J Med 2018;379:215–25 doi:10.1056/NEJMoa1800410 pmid:29766750
    CrossRefPubMed
  10. 10.↵
    1. Hussein  HM, 
    2. Emiru  T, 
    3. Georgiadis  AL, et al
    . Assessment of platelet inhibition by point-of-care testing in neuroendovascular procedures. AJNR Am J Neuroradiol 2013;34:700–06 doi:10.3174/ajnr.A2963 pmid:22422188
    Abstract/FREE Full Text
  11. 11.↵
    1. Maldonado  IL, 
    2. Seris  C, 
    3. Mernes  R, et al
    . Clopidogrel-related platelet inhibition: correlation with perioperative adverse events in neurointerventional procedures. The eJournal of the European Society of Minimally Invasive Neurological Therapy. 2014. http://ejmint.org/sites/default/files/pdf/original_article_1437000160.pdf. Accessed March 14, 2021
  12. 12.↵
    1. Tan  LA, 
    2. Keigher  KM, 
    3. Munich  SA, et al
    . Thromboembolic complications with Pipeline Embolization Device placement: impact of procedure time, number of stents and pre-procedure P2Y12 reaction unit (PRU) value. J NeuroIntervent Surg 2015;7:217–21 doi:10.1136/neurintsurg-2014-011111 pmid:24553344
    Abstract/FREE Full Text
  13. 13.↵
    1. Gandhi  CD, 
    2. Bulsara  KR, 
    3. Fifi  J, et al
    ; SNIS Standards and Guidelines Committee. Platelet function inhibitors and platelet function testing in neurointerventional procedures. J Neurointerv Surg 2014;6:567–77 doi:10.1136/neurintsurg-2014-011357 pmid:25056369
    FREE Full Text
  14. 14.↵
    1. Nordeen  JD, 
    2. Patel  AV, 
    3. Darracott  RM, et al
    . Clopidogrel resistance by P2Y12 platelet function testing in patients undergoing neuroendovascular procedures: incidence of ischemic and hemorrhagic complications. J Vasc Interv Neurol 2013;6:26–34 pmid:23826440
    PubMed
  15. 15.↵
    1. Drazin  D, 
    2. Choulakian  A, 
    3. Nuno  M, et al
    . Body weight: a risk factor for subtherapeutic antithrombotic therapy in neurovascular stenting. J Neurointerv Surg 2011;3:177–81 doi:10.1136/jnis.2010.004085 pmid:21990814
    Abstract/FREE Full Text
  16. 16.↵
    1. Fifi  JT, 
    2. Brockington  C, 
    3. Narang  J, et al
    . Clopidogrel resistance is associated with thromboembolic complications in patients undergoing neurovascular stenting. AJNR Am J Neuroradiol 2013;34:716–20 doi:10.3174/ajnr.A3405 pmid:23194833
    Abstract/FREE Full Text
  17. 17.↵
    1. Flechtenmacher  N, 
    2. Kämmerer  F, 
    3. Dittmer  R, et al
    . Clopidogrel resistance in neurovascular stenting: correlations between light transmission aggregometry, VerifyNow, and the Multiplate. AJNR Am J Neuroradiol 2015;36:1953–58 doi:10.3174/ajnr.A4388 pmid:26272977
    Abstract/FREE Full Text
  18. 18.↵
    1. de Souza  R, 
    2. Pena  MI, 
    3. de Vasconcelos  AV, et al
    . Carotid and vertebral artery stenting: REMAT data (Madre Teresa Registry). Revista Brasileira de Cardiologia Invasiva 2013;21:152–58 doi:10.1016/S2214-1235(15)30124-1
    CrossRef
  19. 19.↵
    1. Asai  T, 
    2. Miyachi  S, 
    3. Izumi  T, et al
    . Relationship between low response to clopidogrel and periprocedural ischemic events with coil embolization for intracranial aneurysms. J Neurointerv Surg 2016;8:752–55 doi:10.1136/neurintsurg-2015-011727 pmid:26109688
    Abstract/FREE Full Text
  20. 20.↵
    1. Daou  B, 
    2. Starke  RM, 
    3. Chalouhi  N, et al
    . P2Y12 reaction units: effect on hemorrhagic and thromboembolic complications in patients with cerebral aneurysms treated with the Pipeline Embolization Device. Neurosurgery 2016;78:27–33 doi:10.1227/NEU.0000000000000978 pmid:26571145
    CrossRefPubMed
  21. 21.↵
    1. Nishi  H, 
    2. Nakahara  I, 
    3. Matsumoto  S, et al
    . Platelet reactivity and hemorrhage risk in neurointerventional procedures under dual antiplatelet therapy. J Neurointerv Surg 2016;8:949–53 doi:10.1136/neurintsurg-2015-011844 pmid:26297788
    Abstract/FREE Full Text
  22. 22.↵
    1. Holmes  DR   Jr., 
    2. Dehmer  GJ, 
    3. Kaul  S, et al
    . Society for Cardiovascular Angiography Interventions, Society of Thoracic Surgeons, Writing Committee Members, ACCF/AHA Clopidogrel clinical alert: approaches to the FDA “boxed warning”: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association. Circulation 2010;122:537–57 doi:10.1161/CIR.0b013e3181ee08ed pmid:20585015
    FREE Full Text
  23. 23.↵
    United States Food & Drug Administration. FDA Drug Safety Communication: Reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fda-drug-safety-communication-reduced-effectiveness-plavix-clopidogrel-patients-who-are-poor. Accessed July 8, 2021
  24. 24.↵
    1. Akbari  SH, 
    2. Reynolds  MR, 
    3. Kadkhodayan  Y, et al
    . Hemorrhagic complications after prasugrel (Effient) therapy for vascular neurointerventional procedures. J Neurointerv Surg 2013;5:337–43 doi:10.1136/neurintsurg-2012-010334 pmid:22555594
    Abstract/FREE Full Text
  25. 25.↵
    1. Atallah  E, 
    2. Saad  H, 
    3. Bekelis  K, et al
    . The use of alternatives to clopidogrel in flow-diversion treatment with the Pipeline Embolization Device. J Neurosurg 2018;129:1130–35 doi:10.3171/2017.5.JNS162663 pmid:29219758
    CrossRefPubMed
  26. 26.
    1. Choi  HH, 
    2. Cho  YD, 
    3. Han  MH, et al
    . Antiplatelet premedication-free stent-assisted coil embolization in acutely ruptured aneurysms. World Neurosurg 2018;114:e1152–60 doi:10.1016/j.wneu.2018.03.164 pmid:29614363
    CrossRefPubMed
  27. 27.↵
    1. Choi  HH, 
    2. Lee  JJ, 
    3. Cho  YD, et al
    . Antiplatelet premedication for stent-assisted coil embolization of intracranial aneurysms: low-dose prasugrel vs clopidogrel. Neurosurgery 2018;83:981–88 doi:10.1093/neuros/nyx591 pmid:29301051
    CrossRefPubMed
  28. 28.↵
    1. Delgado Almandoz  JE, 
    2. Crandall  BM, 
    3. Scholz  JM, et al
    . Pre-procedure P2Y12 reaction units value predicts perioperative thromboembolic and hemorrhagic complications in patients with cerebral aneurysms treated with the Pipeline Embolization Device. J Neurointerv Surg 2013;5:iii3–10 doi:10.1136/neurintsurg-2012-010582 pmid:23314576
    Abstract/FREE Full Text
  29. 29.↵
    1. Delgado Almandoz  JE, 
    2. Crandall  BM, 
    3. Scholz  JM, et al
    . Last-recorded P2Y12 reaction units value is strongly associated with thromboembolic and hemorrhagic complications occurring up to 6 months after treatment in patients with cerebral aneurysms treated with the Pipeline Embolization Device. AJNR Am J Neuroradiol 2014;35:128–35 doi:10.3174/ajnr.A3621 pmid:23828107
    Abstract/FREE Full Text
  30. 30.
    1. Ha  EJ, 
    2. Cho  WS, 
    3. Kim  JE, et al
    . Prophylactic antiplatelet medication in endovascular treatment of intracranial aneurysms: low-dose prasugrel versus clopidogrel. AJNR Am J Neuroradiol 2016;37:2060–65 doi:10.3174/ajnr.A4864 pmid:27390320
    Abstract/FREE Full Text
  31. 31.↵
    1. Higashiguchi  S, 
    2. Sadato  A, 
    3. Nakahara  I, et al
    . Reduction of thromboembolic complications during the endovascular treatment of unruptured aneurysms by employing a tailored dual antiplatelet regimen using aspirin and prasugrel. J Neurointerv Surg 2021 Feb 25. [Epub ahead of print] doi:10.1136/neurintsurg-2020-016994 pmid:33632886
    Abstract/FREE Full Text
  32. 32.
    1. Kurniawan  RG, 
    2. Song  Y, 
    3. Kwon  B, et al
    . Tailored antiplatelet agent medication in clopidogrel hyporesponsive patients before stent-assisted coiling: single-center experience. Neuroradiology 2020;62:1709–15 doi:10.1007/s00234-020-02496-8 pmid:32661570
    CrossRefPubMed
  33. 33.
    1. Lee  D, 
    2. Song  Y, 
    3. Han  M, et al
    . Low-dose prasugrel in patients with resistance to clopidogrel for the treatment of cerebral aneurysms. Neurointervention 2018;13:124–27 doi:10.5469/neuroint.2018.01088 pmid:30196683
    CrossRefPubMed
  34. 34.
    1. Oran  I, 
    2. Cinar  C, 
    3. Gok  M, et al
    . Aggregometry response to half-dose prasugrel in flow-diverting stent implantation. Clin Neuroradiol 2020;30:463–69 doi:10.1007/s00062-019-00804-1 pmid:31165176
    CrossRefPubMed
  35. 35.
    1. Parthasarathy  R, 
    2. Gupta  V, 
    3. Gupta  A
    . Safety of prasugrel loading in ruptured blister like aneurysm treated with a Pipeline Device. Br J Radiol 2018;91:20170476 doi:10.1259/bjr.20170476 pmid:29509490
    CrossRefPubMed
  36. 36.↵
    1. Stetler  WR, 
    2. Chaudhary  N, 
    3. Thompson  BG, et al
    . Prasugrel is effective and safe for neurointerventional procedures. J Neurointerv Surg 2013;5:332–36 doi:10.1136/neurintsurg-2012-010302 pmid:22619468
    Abstract/FREE Full Text
  37. 37.↵
    1. Sedat  J, 
    2. Chau  Y, 
    3. Gaudart  J, et al
    . Prasugrel versus clopidogrel in stent-assisted coil embolization of unruptured intracranial aneurysms. Interv Neuroradiol 2017;23:52–59 doi:10.1177/1591019916669090 pmid:27760885
    CrossRefPubMed
  38. 38.↵
    1. DeGrote  JR, 
    2. Olafson  EM, 
    3. Drofa  A, et al
    . Ticagrelor and acetylsalicylic acid after placement of Pipeline Embolization Device for cerebral aneurysm: a case series. Can J Hosp Pharm 2019;71:349–55
  39. 39.↵
    1. Hanel  RA, 
    2. Taussky  P, 
    3. Dixon  T, et al
    . Safety and efficacy of ticagrelor for neuroendovascular procedures: a single-center initial experience. J Neuronterv Surg 2014;6:320–22 doi:10.1136/neurintsurg-2013-010699
    CrossRef
  40. 40.↵
    1. Kang  HS, 
    2. Kwon  BJ, 
    3. Kim  JE, et al
    . Preinterventional clopidogrel response variability for coil embolization of intracranial aneurysms: clinical implications. AJNR Am J Neuroradiol 2010;31:1206–10 doi:10.3174/ajnr.A2051 pmid:20223886
    Abstract/FREE Full Text
  41. 41.↵
    1. Kim  SH, 
    2. Lee  H, 
    3. Kim  SB, et al
    . Differences in thromboembolism after stent-assisted coiling for unruptured aneurysms between aspirin plus clopidogrel and ticagrelor. J Clin Neurosci 2020;82:128–33 doi:10.1016/j.jocn.2020.10.042 pmid:33317720
    CrossRefPubMed
  42. 42.↵
    1. Mohammaden  MH, 
    2. English  SW, 
    3. Stapleton  CJ, et al
    . Safety and efficacy of ticagrelor as single antiplatelet therapy in prevention of thromboembolic complications associated with the Pipeline Embolization Device (PED): multicenter experience. J Neurointerv Surg 2020;12:1113–16 doi:10.1136/neurintsurg-2020-015978 pmid:32471826
    Abstract/FREE Full Text
  43. 43.↵
    1. Moore  JM, 
    2. Adeeb  N, 
    3. Shallwani  H, et al
    . A multicenter cohort comparison study of the safety, efficacy, and cost of ticagrelor compared to clopidogrel in aneurysm flow diverter procedures. Neurosurgery 2017;81:665–71 doi:10.1093/neuros/nyx079 pmid:28475757
    CrossRefPubMed
  44. 44.↵
    1. Park  KY, 
    2. Ozaki  T, 
    3. Kostynskyy  A, et al
    . Ticagrelor versus clopidogrel in the dual antiplatelet regimen for intracranial stenting or flow-diverter treatment for unruptured cerebral aneurysms: a single-center cohort study. AJNR Am J Neuroradiol 2021;42:1638–44 doi:10.3174/ajnr.A7216 pmid:4244132
    Abstract/FREE Full Text
  45. 45.↵
    1. Soize  S, 
    2. Foussier  C, 
    3. Manceau  PF, et al
    . Comparison of two preventive dual antiplatelet regimens for unruptured intracranial aneurysm embolization with flow diverter/disrupter: a matched-cohort study comparing clopidogrel with ticagrelor. J Neuroradiol 2019;46:378–83 doi:10.1016/j.neurad.2019.01.094 pmid:30731144
    CrossRefPubMed
  46. 46.↵
    1. Narata  AP, 
    2. Amelot  A, 
    3. Bibi  R, et al
    . Dual antiplatelet therapy combining aspirin and ticagrelor for intracranial stenting procedures: a retrospective single center study of 154 consecutive patients with unruptured aneurysms. Neurosurgery 2019;84:77–83 doi:10.1093/neuros/nyy002 pmid:29490066
    CrossRefPubMed
  47. 47.↵
    1. Scott  DM, 
    2. Norwood  RM, 
    3. Parra  D
    . P2Y12 inhibitors in cardiovascular disease: focus on prasugrel. Ann Pharmacother 2009;43:64–76 doi:10.1345/aph.1G726 pmid:19050170
    CrossRefPubMed
  48. 48.↵
    1. Capodanno  D, 
    2. Dharmashankar  K, 
    3. Angiolillo  DJ
    . Mechanism of action and clinical development of ticagrelor, a novel platelet ADP P2Y12 receptor antagonist. Expert Rev Cardiovasc Ther 2010;8:151–18 doi:10.1586/erc.09.172 pmid:20136601
    CrossRefPubMed
  49. 49.↵
    1. Maldonado  IL, 
    2. Machi  P, 
    3. Costalat  V, et al
    . Neuroform stent-assisted coiling of unruptured intracranial aneurysms: short- and midterm results from a single-center experience with 68 patients. AJNR Am J Neuroradiol 2011;32:131–36 doi:10.3174/ajnr.A2245 pmid:20966053
    Abstract/FREE Full Text
  50. 50.↵
    1. Gurbel  PA, 
    2. Bliden  KP, 
    3. Hiatt  BL, et al
    . Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003;107:2908–13 doi:10.1161/01.CIR.0000072771.11429.83 pmid:12796140
    Abstract/FREE Full Text
  51. 51.↵
    1. Koerner  H, 
    2. Derveaux  C, 
    3. Alexandrou  M, et al
    . Do clopidogrel nonresponders have an increased risk of adverse events during supra-aortal angioplasty and stenting? Stroke Res Treat 2012;2012:904534 doi:10.1155/2012/904534 pmid:22577603
    CrossRefPubMed
  52. 52.↵
    1. Angiolillo  DJ, 
    2. Fernandez-Ortiz  A, 
    3. Bernardo  E, et al
    . Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting. Thromb Res 2005;115:101–08 doi:10.1016/j.thromres.2004.07.007 pmid:15567460
    CrossRefPubMedWeb of Science
  53. 53.↵
    1. Karan  V, 
    2. Vyas  D, 
    3. Bohra  V, et al
    . Ticagrelor use in Indian patients undergoing neuroendovascular procedures: a single center experience. Neurointervention 2019;14:125–30 doi:10.5469/neuroint.2019.00087 pmid:31387163
    CrossRefPubMed
  54. 54.↵
    1. Yi  HJ, 
    2. Hwang  G, 
    3. Lee  BH
    . Variability of platelet reactivity on antiplatelet therapy in neurointervention procedure. J Korean Neurosurg Soc 2019;62:3–9 doi:10.3340/jkns.2018.0151 pmid:30630291
    CrossRefPubMed
  55. 55.↵
    1. Goh  C, 
    2. Churilov  L, 
    3. Mitchell  P, et al
    . Clopidogrel hyper-response and bleeding risk in neurointerventional procedures. AJNR Am J Neuroradiol 2013;34:721–26 doi:10.3174/ajnr.A3418 pmid:23275598
    Abstract/FREE Full Text
  56. 56.↵
    1. Nakagawa  I, 
    2. Park  HS, 
    3. Yokoyama  S, et al
    . Influence of diabetes mellitus and cigarette smoking on variability of the clopidogrel-induced antiplatelet effect and efficacy of active management of the target P2Y12 reaction unit range in patients undergoing neurointerventional procedures. J J Stroke Cerebrovasc Dis.2016;25:163–71 doi:10.1016/j.jstrokecerebrovasdis.2015.09.010 pmid:26493334
    CrossRefPubMed
  57. 57.↵
    1. Anderson  CD, 
    2. Biffi  A, 
    3. Greenberg  SM, et al
    . Personalized approaches to clopidogrel therapy: are we there yet? Stroke 2010;41:2997–3002 doi:10.1161/STROKEAHA.110.594069 pmid:21030701
    Abstract/FREE Full Text
  58. 58.↵
    1. Wallentin  L
    . P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. Eur Heart J 2009;30:1964–77 doi:10.1093/eurheartj/ehp296 pmid:19633016
    CrossRefPubMedWeb of Science
  59. 59.↵
    1. Sunderland  N, 
    2. Skroblin  P, 
    3. Barwari  T, et al
    . MicroRNA biomarkers and platelet reactivity: the clot thickens. Circ Res 2017;120:418–35 doi:10.1161/CIRCRESAHA.116.309303 pmid:28104774
    Abstract/FREE Full Text
  60. 60.↵
    1. Zhang  YJ, 
    2. Li  MP, 
    3. Tang  J, et al
    . Pharmacokinetic and pharmacodynamic responses to clopidogrel: evidences and perspectives. Int J Environ Res Public Health 2017;14:301 doi:10.3390/ijerph14030301 pmid:28335443
    CrossRefPubMed
  61. 61.↵
    1. Willeit  P, 
    2. Zampetaki  A, 
    3. Dudek  K, et al
    . Circulating microRNAs as novel biomarkers for platelet activation. Circ Res 2013;112:595–600 doi:10.1161/CIRCRESAHA.111.300539 pmid:23283721
    Abstract/FREE Full Text
  62. 62.↵
    1. Luchessi  AD, 
    2. Silbiger  VN, 
    3. Cerda  A, et al
    . Increased clopidogrel response is associated with ABCC3 expression: a pilot study. Clin Chim Acta 2012;413:417– 21 doi:10.1016/j.cca.2011.10.018 pmid:22040781
    CrossRefPubMed
  63. 63.↵
    1. Su  J, 
    2. Li  X, 
    3. Yu  Q, et al
    . Association of P2Y12 gene promoter DNA methylation with the risk of clopidogrel resistance in coronary artery disease patients. Biomed Res Int 2014;2014:1–8 doi:10.1155/2014/408514 pmid:24745016
    CrossRefPubMed
  64. 64.↵
    1. Neubauer  H, 
    2. Kaiser  AF, 
    3. Endres  HG, et al
    . Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance: the BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy. BMC Med 2011;9:3 doi:10.1186/1741-7015-9-3 pmid:21226927
    CrossRefPubMed
  65. 65.↵
    1. Gasparyan  AY
    . Aspirin and clopidogrel resistance: methodological challenges and opportunities. Vasc Health Risk Manag 2010;6:109–12 doi:10.2147/vhrm.s9087 pmid:20448796
    CrossRefPubMed
  66. 66.↵
    1. Farid  NA, 
    2. Payne  CD, 
    3. Small  DS, et al
    . Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther 2007;81:735–41 doi:10.1038/sj.clpt.6100139 pmid:17361128
    CrossRefPubMedWeb of Science
  67. 67.↵
    1. Siller-Matula  JM, 
    2. Trenk  D, 
    3. Krähenbühl  S, et al
    . Clinical implications of drug-drug interactions with P2Y12 receptor inhibitors. J Thromb Haemost 2014;12:2–13 doi:10.1111/jth.12445 pmid:24406062
    CrossRefPubMed
  68. 68.↵
    1. Gabriel  SA, 
    2. Beteli  CB, 
    3. Tanighuchi  RS, et al
    . Aspirin resistance and atherothrombosis. Rev Bras Cir Cardiovasc 2007;22:96–103 doi:10.1590/s0102-76382007000100017 pmid:17992310
    CrossRefPubMed
  69. 69.↵
    1. Judge  HM, 
    2. Patil  SB, 
    3. Buckland  RJ, et al
    . Potentiation of clopidogrel active metabolite formation by rifampicin leads to greater P2Y12 receptor blockade and inhibition of platelet aggregation after clopidogrel: P2Y12 receptor blockade. J Thromb Haemost 2010;8:1820–27 doi:10.1111/j.1538-7836.2010.03925.x pmid:20492465
    CrossRefPubMed
  70. 70.↵
    1. Bliden  KP, 
    2. DiChiara  J, 
    3. Lawal  L, et al
    . The association of cigarette smoking with enhanced platelet inhibition by clopidogrel. J Am Coll Cardiol 2008;52:531–33 doi:10.1016/j.jacc.2008.04.045 pmid:18687246
    FREE Full Text
  71. 71.↵
    1. Elsherbiny  ME, 
    2. Brocks  DR
    . The ability of polycyclic aromatic hydrocarbons to alter physiological factors underlying drug disposition. Drug Metab Rev 2011;43:457–75 doi:10.3109/03602532.2011.596204 pmid:21823901
    CrossRefPubMed
  72. 72.↵
    1. Desai  NR, 
    2. Mega  JL, 
    3. Jiang  S, et al
    . Interaction between cigarette smoking and clinical benefit of clopidogrel. J Am Coll Cardiol 2009;53:1273–78 doi:10.1016/j.jacc.2008.12.044 pmid:19358940
    FREE Full Text
  73. 73.↵
    1. Sibbing  D, 
    2. von Beckerath  O, 
    3. Schömig  A, et al
    . Impact of body mass index on platelet aggregation after administration of a high loading dose of 600 mg of clopidogrel before percutaneous coronary intervention. Am Jo Cardiol 2007;100:203–05 doi:10.1016/j.amjcard.2007.02.081 pmid:17631070
    CrossRefPubMedWeb of Science
  74. 74.↵
    1. Wong  P, 
    2. Tesoro  E, 
    3. Aletich  V, et al
    . Accumetrics-based clopidogrel dosing in endovascular neurosurgery. Neurol Res 2015;37:998–1005 doi:10.1179/1743132815Y.0000000084 pmid:26344555
    CrossRefPubMed
  75. 75.↵
    1. Ari  H, 
    2. Ozkan  H, 
    3. Karacinar  A, et al
    . The EFFect of hIgh-dose ClopIdogrel treatmENT in patients with clopidogrel resistance (the EFFICIENT trial). Int J Cardiol 2012;157:374–80 doi:10.1016/j.ijcard.2010.12.083 pmid:21239075
    CrossRefPubMed
  76. 76.↵
    1. Collet  JP, 
    2. Hulot  JS, 
    3. Anzaha  G, et al
    . High doses of clopidogrel to overcome genetic resistance: the randomized crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2). JACC Cardiovasc Interv 2011;4:392–402 doi:10.1016/j.jcin.2011.03.002 pmid:21511218
    Abstract/FREE Full Text
  77. 77.↵
    1. Zhuo  X, 
    2. Zhuo  B, 
    3. Ouyang  S, et al
    . Adverse clinical outcomes associated with double dose clopidogrel compared to the other antiplatelet regimens in patients with coronary artery disease: a systematic review and meta-analysis. BMC Pharmacol Toxicol 2018;19:54 doi:10.1186/s40360-018-0247-9 pmid:30176938
    CrossRefPubMed
  78. 78.↵
    1. Shan  J, 
    2. Sun  H
    . The discovery and development of prasugrel. Expert Opin Drug Discov 2013;8:897–905 doi:10.1517/17460441.2013.793668 pmid:23614463
    CrossRefPubMed
  79. 79.↵
    1. Koike  H, 
    2. Asai  F, 
    3. Sugidachi  A, et al
    . Hydropyridine derivatives having antithrombotic activity. CA2077695 1993
  80. 80.↵
    Center for Drug Evaluation and Research. EFFIENT™ Approval letter. (NDA 22-307). https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2009/022307s000_ltr.pdf. Accessed July 8, 2021
  81. 81.↵
    1. Norgard  NB, 
    2. Dinicolantonio  JJ
    . Clopidogrel, prasugrel, or ticagrelor? A practical guide to use of antiplatelet agents in patients with acute coronary syndromes. Postgrad Med 2013;125:91–102 doi:10.3810/pgm.2013.07.2682 pmid:23933898
    CrossRefPubMed
  82. 82.↵
    1. Wiviott  SD, 
    2. Braunwald  E, 
    3. Angiolillo  DJ, et al
    . Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation 2008;118:1626–36 doi:10.1161/CIRCULATIONAHA.108.791061 pmid:18757948
    Abstract/FREE Full Text
  83. 83.↵
    1. Montalescot  G, 
    2. Wiviott  SD, 
    3. Braunwald  E, et al
    ; TRITON-TIMI 38 Investigators. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 2009;373:723–31 doi:10.1016/S0140-6736(09)60441-4 pmid:19249633
    CrossRefPubMedWeb of Science
  84. 84.↵
    1. Wiviott  SD, 
    2. Braunwald  E, 
    3. McCabe  CH, et al
    . Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001–15 doi:10.1056/NEJMoa0706482 pmid:17982182
    CrossRefPubMedWeb of Science
  85. 85.↵
    1. Ogawa  A, 
    2. Toyoda  K, 
    3. Kitagawa  K, et al
    ; PRASTRO-I Study Group. Comparison of prasugrel and clopidogrel in patients with non-cardioembolic ischaemic stroke: a phase 3, randomised, non-inferiority trial (PRASTRO-I). Lancet Neurol 2019;18:238–47 doi:10.1016/S1474-4422(18)30449-6 pmid:30784555
    CrossRefPubMed
  86. 86.↵
    1. Kitagawa  K, 
    2. Toyoda  K, 
    3. Kitazono  T, et al
    . Safety and efficacy of prasugrel in elderly/low body weight Japanese patients with ischemic stroke: randomized PRASTRO-II. Cerebrovasc Dis 2020;49:152–59 doi:10.1159/000506825 pmid:32208397
    CrossRefPubMed
  87. 87.↵
    United States Food & Drug Administration. Highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022307s018lbl.pdf. Accessed July 8, 2021
  88. 88.↵
    1. Byrne  JV
    . Tutorials in Endovascular Neurosurgery and Interventional Neuroradiology. Springer International Publishing; 2017
  89. 89.↵
    1. Jeong  YH, 
    2. Bliden  KP, 
    3. Antonino  MJ, et al
    . Usefulness of the VerifyNow P2Y12 assay to evaluate the antiplatelet effects of ticagrelor and clopidogrel therapies. Am Heart J 2012;164:35–42 doi:10.1016/j.ahj.2012.03.022 pmid:22795280
    CrossRefPubMedWeb of Science
  90. 90.↵
    1. Gurbel  PA, 
    2. Bliden  KP, 
    3. Butler  K, et al
    . Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation 2010;121:1188–99 doi:10.1161/CIRCULATIONAHA.109.919456 pmid:20194878
    Abstract/FREE Full Text
  91. 91.↵
    1. Dobesh  PP, 
    2. Oestreich  JH
    . Ticagrelor: pharmacokinetics, pharmacodynamics, clinical efficacy, and safety. Pharmacotherapy 2014;34:1077–90 doi:10.1002/phar.1477 pmid:25164528
    CrossRefPubMed
  92. 92.↵
    1. Teng  R, 
    2. Mitchell  PD, 
    3. Butler  KA
    . Pharmacokinetic interaction studies of co-administration of ticagrelor and atorvastatin or simvastatin in healthy volunteers. Eur J Clin Pharmacol 2013;69:477–87 doi:10.1007/s00228-012-1369-4 pmid:22922682
    CrossRefPubMed
  93. 93.↵
    1. Gurbel  PA, 
    2. Bliden  KP, 
    3. Butler  K, et al
    . Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET Study. Circulation 2009;120:2577–85 doi:10.1161/CIRCULATIONAHA.109.912550 pmid:19923168
    Abstract/FREE Full Text
  94. 94.↵
    1. James  SK, 
    2. Roe  MT, 
    3. Cannon  CP, et al
    ; PLATO Study Group. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. BMJ 2011;342:d3527 doi:10.1136/bmj.d3527 pmid:21685437
    Abstract/FREE Full Text
  95. 95.↵
    1. Wallentin  L, 
    2. Becker  RC, 
    3. Budaj  A, et al
    . Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045–57 doi:10.1056/NEJMoa0904327 pmid:19717846
    CrossRefPubMedWeb of Science
  96. 96.↵
    1. Johnston  SC, 
    2. Amarenco  P, 
    3. Albers  GW, et al
    ; SOCRATES Steering Committee and Investigators. Ticagrelor versus aspirin in acute stroke or transient ischemic attack. N Engl J Med 2016;375:35–43 doi:10.1056/NEJMoa1603060 pmid:27160892
    CrossRefPubMed
  97. 97.↵
    1. Johnston  SC, 
    2. Amarenco  P, 
    3. Denison  H, et al
    ; THALES Investigators. Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA. N Engl J Med 2020;383:207–17 doi:10.1056/NEJMoa1916870 pmid:32668111
    CrossRefPubMed
  98. 98.↵
    1. Godier  A, 
    2. Taylor  G, 
    3. Gaussem  P
    . Inefficacy of platelet transfusion to reverse ticagrelor. N Engl J Med 2015;372:196–97 doi:10.1056/NEJMc1409373 pmid:25564918
    CrossRefPubMed
  99. 99.↵
    1. Bertling  A, 
    2. Fender  AC, 
    3. Schungel  L, et al
    . Reversibility of platelet P2Y12 inhibition by platelet supplementation: ex vivo and in vitro comparisons of prasugrel, clopidogrel and ticagrelor. J Thromb Haemost 2018;16:1089–98 doi:10.1111/jth.14014 pmid:29582544
    CrossRefPubMed
  100. 100.↵
    1. Bhatt  DL, 
    2. Pollack  CV, 
    3. Weitz  JI, et al
    . Antibody-based ticagrelor reversal agent in healthy volunteers. N Engl J Med 2019;380:1825–33 doi:10.1056/NEJMoa1901778 pmid:30883047
    CrossRefPubMed
  


  
  



  




  


  
  



  
      
  
  

    
  


  
  



  
      
  
  

     Back to top  


  
  



			

		

		
		

			

			  

  
        
In this issue

    
  
  

    
  


  
  



  
      
  
  

    

  

    

  
      
  
  

    


Advertisement



  



  


  
  



  



  


  
  



  
      
  
  

    

	  
  

		

          

            

  
      
  
  

     Print  


  
  



  
      
  
  

     Download PDF  


  
  



  
      
  
  

    
 Email Article
  


  
  



  
      
  
  

    
 Citation Tools
  


  
  



          

        

        
        

          

            



  
      
  
  

    

  

    

  
      
  
  

    

  
  
  
  
      
Safety of Oral P2Y12 Inhibitors in Interventional Neuroradiology: Current Status and Perspectives
  
    	
L.M. Camargo, P.C.T.M. Lima, K. Janot, I.L. Maldonado

  
    	
 American Journal of Neuroradiology Dec 2021, 42 (12) 2119-2126; DOI: 10.3174/ajnr.A7303 

  
  
  



  


  
  



  
      
  
  

    

  
    
  
  
    
  
  
    
  


  


  
  



  
      
  
  

    
del.icio.us logo Twitter logo Facebook logo Mendeley logo
  


  
  



  



  


  
  



  
      
  
  

    
  


  
  



          

        

	
 	
	
	


  


  
  



  
      
  
  

    
              Purchase  


  
  



  
        
Jump to section

    
  
  

    
  


  
  



  
      
  
  

    
  


  
  



			

		

	
	
 	
	
	


    

  



  

                
    

      

  

    

  
      
  
  

    


Advertisement